Pieter H. M. van Baal

Pieter H. M. van Baal

Auto-generated profile, based on publicly available information

Pieter H. M. van Baal

Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2008 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
PBPieter H. M van Baal
Pieter H. M van Baal
JPJohan J Polder
Johan J Polder
GWG. Ardine de Wit
G. Ardine de Wit
RHRudolf T Hoogenveen
Rudolf T Hoogenveen
TFTalitha L Feenstra
Talitha L Feenstra
WBWerner B. F Brouwer
Werner B. F Brouwer
Obesity is a major cause of morbidity and mortality and is associated with high medical expenditures. It has been suggested that obesity prevention could result in cost savings. The objective of this study was to estimate the annual and lifetime medical costs attributable to obesity, to compare those to similar costs attributable to smoking, and to discuss the implications for prevention. With a simulation model, lifetime health-care costs were estimated for a cohort of obese people aged 20 y at baseline. To assess the impact of obesity, comparisons were made with similar cohorts of smokers and “healthy-living” persons (defined as nonsmokers with a body mass index between 18.5 and 25). Except for relative risk values, all input parameters of the simulation model were based on data from The Netherlands. In sensitivity analyses the effects of epidemiologic parameters and cost definitions were assessed. Until age 56 y, annual health expenditure was highest for obese people. At older ages, smokers incurred higher costs. Because of differences in life expectancy, however, lifetime health expenditure was highest among healthy-living people and lowest for smokers. Obese individuals held an intermediate position. Alternative values of epidemiologic parameters and cost definitions did not alter these conclusions. Although effective obesity prevention leads to a decrease in costs of obesity-related diseases, this decrease is offset by cost increases due to diseases unrelated to obesity in life-years gained. Obesity prevention may be an important and cost-effective way of improving public health, but it is not a cure for increasing health expenditures.

5 September 2018 in The European Journal of Health Economics
Verified
Journal Article
Closed access
PDF file
WBWerner Brouwer
Werner Brouwer
PBPieter van Baal
Pieter van Baal
NEN.J.A. Van Exel
N.J.A. Van Exel
MVMatthijs Versteegh
Matthijs Versteegh

1 December 2011 in American Journal of Public Health
Verified
Journal Article
Closed access
IMIstvan M. Majer
Istvan M. Majer
WNWilma J. Nusselder
Wilma J. Nusselder
JMJohan P. Mackenbach
Johan P. Mackenbach
BKBart Klijs
Bart Klijs
PBPieter H. M. van Baal
Pieter H. M. van Baal
Objectives. We assessed the association between mortality and disability and quantified the effect of disability-associated risk factors. Methods. We linked data from cross-sectional health surveys in the Netherlands to the population registry to create a large data set comprising baseline covariates and an indicator of death. We used Cox regression models to estimate the hazard ratio of disability on mortality. Results. Among men, the unadjusted hazard ratio for activities of daily living, mobility, or mild disability defined by the Organization for Economic Co-operation and Development at age 55 years was 7.85 (95% confidence interval [CI] = 4.36, 14.13), 5.21 (95% CI = 3.19, 8.51), and 1.87 (95% CI = 1.58, 2.22), respectively. People with disability in activities of daily living and mobility had a 10-year shorter life expectancy than nondisabled people had, of which 6 years could be explained by differences in lifestyle, sociodemographics, and major chronic diseases. Conclusions. Disabled people face a higher mortality risk than nondisabled people do. Although the difference can be explained by diseases and other risk factors for those with mild disability, we cannot rule out that more severe disabilities have an independent effect on mortality.

1 March 2011 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
PBPieter H.M. van Baal
Pieter H.M. van Baal
AWAlbert Wong
Albert Wong
LSLaurentius C.J. Slobbe
Laurentius C.J. Slobbe
JPJohan J. Polder
Johan J. Polder
WBWerner B.F. Brouwer
Werner B.F. Brouwer
GWG. Ardine de Wit
G. Ardine de Wit

11 March 2011 in Health Economics
Verified
Journal Article
Closed access
PDF file
AWAlbert Wong
Albert Wong
PBPieter H. M. van Baal
Pieter H. M. van Baal
HBHendriek C. Boshuizen
Hendriek C. Boshuizen
JPJohan J. Polder
Johan J. Polder

1 January 2008 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
DRDavid R. Rappange
David R. Rappange
PBPieter H. M. van Baal
Pieter H. M. van Baal
NEN.J.A. Van Exel
N.J.A. Van Exel
TFTalitha L. Feenstra
Talitha L. Feenstra
FRFrans F. H. Rutten
Frans F. H. Rutten
WBWerner B. F. Brouwer
Werner B. F. Brouwer